Program: posters

Oral poster sessions

Poster presentations are only made in person during dedicated sessions, they are not broadcast but the files can be viewed on the platform if you are registered for the meeting once the event ends.

Poster booths A, B, C, D and E are located in the booth area, between the auditorium and the terrasse.
Each presentation is 7 min long including Q&A, followed by 2 min free between each presentations.

Screen Time #ref
Poster session 1 on Oct. 24th — from 15:45 to 16:30
Moderator: Akihiko IKOMA, Japan
A 15:30 #761 Robin ROHAYEM Effect of a skin pH reducing emollient on the skin microbiome in the context of atopic dermatitis
15:39 #438 Febu JOYQuality of Life in Adult Patients with Atopic Dermatitis in Qatar
15:48 #429 Roberto TAKAOKA Atopic Dermatitis Patient’s Journey through the Healthcare System in Brazil
15:57 #538 Robin ROHAYEM Topical and systemic immunomodulatory therapies and the skin microbiome in atopic dermatitis: A pilot study from the CK-Care ProRaD cohort
16:06 #411 Amina Nomtondo OUEDRAOGO Direct medical cost of emollients in the management of atopic dermatitis in Ouagadougou
Moderator: Sara AL KHAWAGA
B 15:39 #405 Hye-One KIM Analysis of Skin Microbiota and Tryptophan Metabolites in Children with Atopic Dermatitis
15:48 #362 Naoko HATTORI Delayed blanch Phenomenon to Acetylcholine and Its Association with Sweating Function in Atopic Dermatitis: A Case Study
15:57 #465 Bérénice DEGBOE Atopic dermatitis in adults : clinical forms and associated comorbidities from 2019-2023 in the University Clinic of Dermatology-Venerology of NUHC-HKM, Cotonou (Benin)
16:06 #534 William Wael JEBRIL Individuals with Darier disease have an increased risk of suicide and self-injurious behaviours
Moderator: Dirk JAN HIJNEN, Netherlands
C 15:30 #392 Young Bok LEE Transcriptomic Insights into Prurigo Nodularis: Unraveling Neuronal Profiles and Immune Response
15:39 #490 Alain TAÏEB Moisturizers for Atopic Dermatitis (AD): the ISAD-WHO application to include registered creams in the core list of the essential medicines’ lists (EML and EMLc).
15:48 #400 Jiehyun JEON Disease Modification of Methotrexate in Atopic Dermatitis with Decreasing Eosinophils and Specific Immunoglobulin E – Pilot Study
15:57 #368 Chang Ook PARK The Future of Atopic Dermatitis Care: Defining Endophenotypes and Exploring Biomarkers for precision medicine
16:06 #415 Mohammed Nasser AL-ABDULLA Successful treatment of Prurigo Nodularis in a Pediatric Patient using anti-Il-4 receptor-A antibody Dupilumab
Moderator: Medhat ASKAR, Qatar
D 15:30 #395 Celestin Kouadio AHOGO Atopy School: First experience in French-speaking Sub-Saharan Africa, Acquisitions, challenges and outlook
15:39 #369 Yu Ri WOO Differential expression of antimicrobial peptides in scalp dermatitis among patients with atopic dermatitis
15:48 #559 Abdul Mannan MUSTAFA Knowledge, attitude and practices of Primary healthcare providers reagarding Atopic Dermatitis in Multan, Pakistan
15:57 #366 Sailan WANG Investigating the role of the FLG2 gene in Atopic Dermatitis in the Swedish population
16:06 #452 Ga-Young LEE The Correlation between EASI Score and Multiple Allergen Simultaneous Test (MAST) Results in Atopic Dermatitis Patients
Moderator: Majid Ali ALAM, Qatar
E 15:30 #332 Kiran GODSE Atopic dermatitis in Indian skin
15:39 #387 Tsiory Iarintsoa RAZAFIMAHARO Association between atopic dermatitis and leprosy
15:48 #319 Sinu Rose MATHACHAN The prevalence and severity of atopic dermatitis and the pattern of pediatric dermatoses: A six-month study from a multispecialty clinic in Dubai, UAE
15:57 #322 Fatimh Hussain ALMARRI Topical Corticosteroid Phobia Among Caregivers Of Children With Atopic Dermatitis: A Cross-Sectional Study Using TOPICOP Score In Saudi Arabia
16:06 #357 Yousef DASHTI The microbiome in inflammatory skin disorders: The Inner Workings of The Outer Surface
Poster session 2 on Oct. 25th — from 09:30 to 10:00
Moderator: Arturo BORZUTZKY, Chile
A 09:30 #402 Weronika ZYSK Can we predict dupilumab treatment outcomes in adult patients with atopic dermatitis? A retrospective single-center study
09:39 #333 Delphine STAUMONT-SALLÉ Switching from Dupilumab to Tralokinumab or JAK inhibitors in cases of ocular and/or facial adverse events: a real-life experience
09:48 #774 Martin DOSSENBACK Lebrikizumab versus Other Systemic Monotherapies for Moderate-to-Severe Atopic Dermatitis: A Network Meta-analysis of Short-term Efficacy
Moderator: Akihiko IKOMA, Japan
B 09:30 #399 Hye-One KIM Comparison of Skin Transcriptomes from Biopsies in Prurigo Patients with and without Atopic Dermatitis
09:39 #446 Mike BASTIAN Optimal itch response with dupilumab irrespective of EASI outcome in adult patients with moderate-to-severe AD
09:48 #461 Yoko KATAOKA Abnormally elevated serum TARC may predict secondary ineffectiveness of systemic JAK inhibitors
Moderator: Sébastien BARBAROT, France
C 09:30 #434 Fengxian LI A topical Chinese herbal inhibits pruritus and skin inflammation via neural TRPM8 in atopic dermatitis
09:39 #344 Brad WOODIE Compared with dupilumab non-prescribers, dupilumab prescribers practice more evidence-based guideline care: fewer prescribed days of systemic corticosteroids and more days of topical corticosteroid-sparing agents
09:48 #769 Magdalena TRZECIAK Contact sensitization to topical medications in patients with symptoms of allergic contact dermatitis, with and without atopic dermatitis – a 10-year retrospective analysis of patch test results
Moderator: Georg STINGL, Austria
D 09:30 #299 Mutong ZHAO Upadacitinib for Refractory Pediatric Atopic Dermatitis: A Real-World Study on Effectiveness and Safety in Dupilumab Non-Responders
09:39 #373 Seong Jun SEO Effectiveness of Non-Live Recombinant Herpes Zoster Vaccine in Reducing Herpes Simplex Virus Reactivation in Atopic Dermatitis Patients Treated with Janus Kinase Inhibitors
09:48 #333 Delphine STAUMONT-SALLÉ Switching from Dupilumab to Tralokinumab or JAK inhibitors in cases of ocular and/or facial adverse events: a real-life experience
Moderator: Kiran GODSE, India
E 09:30 #356 Yousef DASHTI Complications of Dupilumab Therapy: A Literature Review of Side Effects and Clinical Case Report of Renal Adverse Event
09:39 #335 Andreas WOLLENBERG Improvements in itch and sleep disturbance are maintained up to Week 48 with nemolizumab plus TCS/TCI treatment in patients with moderate-to-severe atopic dermatitis: Results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)
09:48 #485 Park SU JUNG Is Eczema Area and Severity Index score ³23 a suitable cut-off for severe atopic dermatitis?
Poster session 3 on Oct. 25th — from 15:15 to 16:00
Moderator: Kiran GODSE, India
A 15:15 #458 Florine MANJARIMANANA Treatment satisfaction of parents of children with atopic dermatitis treated with dermocorticoids
15:24 #462 Wei LI Abrocitinib rapidly and extensively normalizes dysregulated blood transcriptome of atopic dermatitis patients
15:33 #PSG Peter SCHMID-GRENDELMEIER Allergic contact dermatitis due to hair adhesives
15:42 #766 Gloria Elisante MASENGA Quality of life among adult atopic dermatitis patients attending the regional dermatology training center in Northern Tanzania
Moderator: Majid Ali ALAM, Qatar
B 15:15 #303 Atsushi OTSUKA Effectiveness and Safety of Nemolizumab in Treating Atopic Dermatitis Among Japanese Patients: A Retrospective Study at a Single Center
15:24 #407 Sun Young CHOI Ameliorative effects of escin on inflammation via Glucocorticoid Receptor in atopic dermatitis mouse model
15:33 #337 Yi Na YOON Dupilumab Associated Head and Neck Dermatitis with Conjunctivitis: A Case Series
15:42 #763 Sang Eun LEE Distinct transcriptomic profiles of sensory neurons in mouse model of atopic dermatitis and psoriasis: insight into the mechanism of chronic itch in atopic dermatitis and psoriasis
Moderator: Akihiko IKOMA, Japan
C 15:15 #457 Ana B. ROSSI Dupilumab Monotherapy Prevents Flares and Provides Sustained Control of Atopic Dermatitis Over 1 Year Across Various Dosing Frequencies
15:24 #379 Carsten FLOHR Living network meta-analysis of systemic treatments for atopic dermatitis
15:33 #397 Thomas BIEBER Maintenance of Optimal Response Over 2 Years in Patients With Atopic Dermatitis Treated With Dupilumab
15:42 #767 Arturo BORZUTZKY Lipidomics of vernix caseosa is modified by maternal overweight/obesity and associates with development of atopic dermatitis in the offspring
Moderator: Alain TAÏEB, France
D 15:15 #454 Andreas WOLLENBERG Treatment with tralokinumab provides long-term control of head and neck atopic dermatitis
15:24 #439 Annie ZHANG Real-World treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 4-year results from the PEDISTAD Registry
15:33 #422 Pontus Olov Allan JONSSON Drug survival of systemic treatments for atopic dermatitis in Sweden
15:42 #651 Erere OTROFANOWEI Clinical and biophysical parameters of patients with Atopic Dermatitis in Nigeria and correlation with disease severity
Moderator: Georg STINGL, Austria
E 15:15 #343 Mahsa TAYEFI Body weight and tryptophan/kynurenine metabolites during treatment with dupilumab
15:24 #405 Hye-One KIM Analysis of Skin Microbiota and Tryptophan Metabolites in Children with Atopic Dermatitis
15:33 #325 Hyounchang KO Oral cyclosporine for pediatric atopic dermatitis: A real-world experience of efficacy and safety
15:42 #386 Justyna SZCZĘCH TADPol study: a real-world evidence on dupilumab and upadacitinib in the treatment of moderate-to-severe atopic dermatitis in Poland
Poster session 4 on Oct. 26th — from 10:35 to 11:00
Moderator: Kiran GODSE, India
A 10:35 #430 Jensen YEUNG Clinical adverse events with upadacitinib in adolescent and adult patients with atopic dermatitis: interim analysis of a real-world multicentre retrospective review
10:44 #355 Mike BASTIAN Understanding the Patient’s Perception: Which EASI Threshold is Clinically Meaningful to Patients With Atopic Dermatitis?
10:53 #441 Annie ZHANG Growth Analysis at Baseline in Children and Adolescents With Moderate-to-Severe Atopic Dermatitis Enrolled in Phase 3 Dupilumab Trials
Moderator: Georg STINGL, Austria
B 10:35 #432 Neal KOLLER Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalfin
10:44 #762 Erere OTROFANOWEI Sensitization to mites and cockroaches is highly predominant in atopic dermatitis patients in Nigeria – a pilot study from Lagos
10:53 #364 Eung Ho CHOI Analysis of Patch Test Results Focusing on Atopic History in Rosacea Patients: A Retrospective Study
Moderator: Majid Ali ALAM, Qatar
C 10:35 #367 Chia-Yu CHU Disease burden and treatment preference for moderate-to-severe atopic dermatitis in Taiwan: a discrete-choice experiment
10:44 #428 Roberto TAKAOKA Creating a Model for Evaluating Healthcare Disparities in the Accessibility of Treatments for Atopic Dermatitis
10:53 #380 Ana B. ROSSI Dupilumab Improves Quality of Life in Patients With Atopic Hand and/or Foot Dermatitis
Moderator: Akihiko IKOMA, Japan
D 10:35 #371 Byeol HAN Real-world Prevalence and Associated Factors of Nipple Eczema in Patients with Atopic Dermatitis
10:44 #436 Annie ZHANG Impact of Dupilumab Treatment on Seasonal Disease Severity in Adults With Moderate-to-Severe Atopic Dermatitis
10:53 #427 Amina Nomtondo OUEDRAOGO Knowledge attitudes practices of atopic patients in Ouagadougou
Moderator: Fang WANG, China
E 10:35 #378 Carsten FLOHR The Global Atopic Dermatitis Atlas: A Systematic Review Mapping Global Burden of Atopic Dermatitis
10:44 #414 John C. SU Identifying risk factors related to social disadvantage in atopic dermatitis patients who are referred to an Australian paediatric tertiary referral centre
10:53 #365 Dong hun LEE Early-life dietary factors and risk of persistent atopic dermatitis: A nationwide cohort and cross-sectional study
Poster session 5 on Oct. 26th — from 15:20 to 16:00
Moderator: Georg STINGL, Austria
A 15:20 #396 Annie ZHANG Dupilumab reduces lesion severity and extent in children <12 years of age with moderate-to-severe AD: interim results from the PEDISTAD real-world registry
15:29 #377 Shin MIN-KYUNG Classification of facial involvement in atopic dermatitis
15:38 #381 Fenohasina RAKOTONANDRASANA Association of Tralokinumab and Adalimumab: Good tolerance and efficacy in a case of severe atopic dermatitis and juvenile idiopathic arthritis
15:47 #773 Thomas BIEBER EASI 90 Response Sustained up to 38 Weeks After Lebrikizumab Withdrawal Despite Negligible Serum Concentrations
Moderator: Akihiko IKOMA, Japan
B 15:20 #320 Shan WANG Real-World Treatment Outcomes of Dupilumab and Baseline Health Economic Burden in Children and Adolescents with Moderate-to-Severe Atopic Dermatitis: Results from the ADOPED-STAD Study in China
15:29 #460 Wei LI Temporal and topographical heterogeneities in clinical manifestations of atopic dermatitis revealed by a non-selective registry in China
15:38 #661 Xin Yi N Exploring the link between Mind and Skin: understanding the neurocutaneous axis in atopic dermatitis
Moderator: Kiran GODSE, India
C 15:20 #376 John CHITTOCK Optical Coherence Tomography Differentiates Skin Atrophogenicity of Topical Anti-inflammatory Treatments in Patients With Atopic Dermatitis
15:29 #449 John C. SU Dupilumab Efficacy and Safety up to 2 Years in Children Aged 6 Months to 5 Years With Moderate-to-Severe Atopic Dermatitis
15:38 #330 Pranvera SULEJMANI The Global Reach of Artificial Intelligence in Atopic Dermatitis
Moderator: Majid Ali ALAM, Qatar
D 15:20 #431 Vimal H. PRAJAPATI Use of systemic Janus kinase inhibitors for pediatric atopic dermatitis: a systematic review of randomized controlled trials